Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

OncoMed

- PMLiVE

GSK terminates lung cancer vaccine trial

Unable to identify patients who may benefit from MAGE-A3 immunotherapy

- PMLiVE

Pfizer says Xalkori tops chemo as first line therapy

Superior progression free survival for lung cancer patients

- PMLiVE

GSK’s cancer vaccine flunks another trial

MAGE-A3 fails to improve survival in lung cancer patients

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

Roche - Basel

Roche drug fails in lung cancer trial

Damages prospects for onartuzumab

- PMLiVE

NICE set to reject Lilly’s Alimta for new use in lung cancer

Drug deemed not cost-effective use of NHS resources in new indication

- PMLiVE

Lilly’s ramucirumab boosts survival in lung cancer

Late-stage trial backs regulatory prospects

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

Boehringer to help promote genetic biomarker testing

Will support Bonnie J Addario Lung Cancer Foundation

- PMLiVE

Michael Wyzga OncoMed board

He brings financial experience from Genzyme

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links